key: cord-0791420-cpd07nir
authors: Soni, Dharmendra Kumar; Cabrera-Luque, Juan; Kar, Swagata; Sen, Chaitali; Devaney, Joseph; Biswas, Roopa
title: Suppression of miR-155 attenuates lung cytokine storm induced by SARS-CoV-2 infection in human ACE2-transgenic mice
date: 2020-12-17
journal: bioRxiv
DOI: 10.1101/2020.12.17.423130
sha: a2ceecba927cbbcdc5a53e5d5c788b9ecc28dc31
doc_id: 791420
cord_uid: cpd07nir

Coronavirus disease 2019 (COVID-19) is a recent global pandemic. It is a deadly human viral disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with a high rate of infection, morbidity and mortality. Therefore, there is a great urgency to develop new therapies to control, treat and prevent this disease. Endogenous microRNAs (miRNAs, miRs) of the viral host are key molecules in preventing viral entry and replication, and building an antiviral cellular defense. Here, we have analyzed the role of miR-155, one of the most powerful drivers of host antiviral responses including immune and inflammatory responses, in the pathogenicity of SARS-CoV-2 infection. Subsequently, we have analyzed the potency of anti-miR-155 therapy in a COVID-19 mouse model (mice transgenic for human angiotensin I-converting enzyme 2 receptor (tg-mice hACE2)). We report for the first time that miR-155 expression is elevated in COVID-19 patients. Further, our data indicate that the viral load as well as miR-155 levels are higher in male relative to female patients. Moreover, we find that the delivery of anti-miR-155 to SARS-CoV-2-infected tg-mice hACE2 effectively suppresses miR-155 expression, and leads to improved survival and clinical scores. Importantly, anti-miR-155-treated tg-mice hACE2 infected with SARS-CoV-2 not only exhibit reduced levels of pro-inflammatory cytokines, but also have increased anti-viral and anti-inflammatory cytokine responses in the lungs. Thus, our study suggests anti-miR-155 as a novel therapy for mitigating the lung cytokine storm induced by SARS-CoV-2 infection.

Coronavirus disease 2019 (COVID-19) is a life-threatening human viral disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and accountable for the high rate of infection, hospitalization, morbidity and mortality around the world. The outbreak of this deadly human viral pathogen was first reported in December 2019 in Wuhan city of China (1, 2) . Subsequently, due to its exceedingly high rate of human-to-human transmission and infection, SARS-CoV-2 rapidly transmitted throughout the world with a very high prevalence, leading to a global pandemic. As of December 8, 2020, almost all (177) countries/regions have reported more than 67,781,393 cases of patients infected with SARS-CoV-2, and 1,548,516 deaths, worldwide, and this continues to rise at an exponential rate (https://coronavirus.jhu.edu/map.html) (3) . Therefore, there is great urgency to curb the spread of SARS-CoV-2 and treat infected patients, by developing new therapies to control, treat and prevent this disease. To date, a diverse array of therapeutics COVID-19 is in phase three clinical trial to, such as two mRNA-based vaccine candidate, mRNA-1273 (NIAID and Moderna, Inc.) and BNT162b2 (Pfizer and BioNTech), and a vaccine developed against the SARS-CoV-2 virus spike protein, AZD1222 (University of Oxford and AstraZeneca). Despite the rapid pace with which researchers and manufacturers are moving potential therapeutics into clinical trials, developing effective countermeasures against COVID-19 remains an unmet goal.

The upper respiratory tract is the main site for active replication of SARS-CoV-2, and the severity of the disease depends upon the expression of the viral receptor by lung epithelial cells (4) (5) (6) . Further, increased inflammatory responses and cytokine storm (such as interleukin (IL)-1β IL-2, IL-6, IL-7, IL-8, tumor necrosis factor-α (TNF-α), granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF)) have been reported in the lungs of severe COVID-19 patients (7) (8) (9) . In addition, elevated expression of numerous chemokines (monocyte chemoattractant protein 1 (MCP1), interferonγ inducible protein 10 (IP10) and macrophage inflammatory protein 1-α (MIP1-α)) have also been reported in COVID-19 patients (7, 9, 10) . These Recently, microRNAs (miRNAs, miRs), short (~22 nucleotides) endogenous noncoding RNAs, have emerged as prominent regulators of human defense mechanisms in airway inflammation, lung diseases as well as in various acute respiratory distress syndromes (ARDS).

Importantly, in viral infection and disease, the host's endogenous miRNAs have a decisive function in preventing viral entry and replication either by direct degradation of viral RNA or suppression of translation of proteins involved in replication (11, 12) . Furthermore, miRNAs play a predominant role in building antiviral cellular defense and are critical regulators of host immunity and inflammatory responses by inducing mRNA degradation and/or repressing mRNA translation of target genes (13, 14) . Over 60% of human genes are targets of miRNAs and are regulated by miRNAs (15, 16) . Altered expression of specific miRNAs have been demonstrated in a variety of human diseases including cancer, heart disease, immunological disorders, and diabetes (17) (18) (19) (20) (21) (22) . Notably, studies have illustrated the association of several miRNAs with immune response against various respiratory viruses such as influenza virus (IV), respiratory syncytial virus (RSV), human rhinovirus (hRV), human metapneumovirus (hMPV), and human coronavirus (HcoV) (12, 23, 24) . Some miRNAs regulate levels of immunomodulating factors and suppress or promote inflammatory responses (25) . Moreover, since a single miRNA targets multiple genes and modulates the expression of these genes, the best way to nullify the consequence of a dysregulated miRNA in diseased cells, is to restore or inhibit expression (26) . Single miRNAs have been shown to stimulate therapeutic responses in animal disease models as well as in human clinical trials (26) (27) (28) (29) . Therefore, miRNA replacement or inhibitor-based therapeutic mechanisms can be exploited to prevent viral entry or replication and/or restore or modulate host immune responses against COVID-19.

MiR-155, a well-studied miRNA, is one of the most powerful regulators of host antiviral responses including immune and inflammatory responses (30) (31) (32) (33) . In recent years, numerous studies have clearly established that miR-155 is evolutionarily conserved and during viral infections, its expression is consistently elevated in different cell systems in both human and animal models (34) (35) (36) (37) (38) (39) . Furthermore, the role of elevated miR-155 is also correlated with lung inflammation, severity of disease and higher mortality in animal models of ARDS (40) (41) (42) (43) . Interestingly, suppression of miR-155 reduces lung inflammation and induce more rapid recovery of mice infected with respiratory viral pathogens (42, 43) . Likewise, knock out (KO) of miR-155 or treatment with anti-miR-155 suppresses cigarette smoke-induced lung inflammation in mice models (44) . These studies emphasize the role of miR-155 in the modulation of host defense responses during respiratory virus infection. Our data indicate that miR-155 expression is significantly elevated in COVID-19 patients.

Interestingly, a relatively higher SARS-CoV-2 viral load and miR-155 expression are observed in male COVID-19 patients compared to female patients. Further, our data demonstrate that treatment of SARS-CoV-2-infected tg-mice with anti-miR-155 is effective in suppression of miR-155 expression in the lung tissues, and also promotes improved survival as well as a slight increase in body weight. Moreover, anti-miR-155-treated tg-mice have reduced expression of pro-inflammatory cytokines as well as increased anti-viral and anti-inflammatory cytokines responses in the lungs. These data collectively suggest anti-miR-155 as a novel therapy for mitigating the lung cytokine storm induced by SARS-CoV-2 infection.

In order to determine the SARS-CoV-2 viral load in COVID-19 patients, a total of 99 human subjects were examined using nasopharyngeal swabs. The isolated RNA was analyzed using COVID-19 RT-PCR diagnostic kit with probes specific for SARS-CoV patients. However, we acknowledge that larger sample size is required to establish these observations.

We analyzed the expression level of miR-155 in the RNA isolated from nasopharyngeal swabs of 99 human subjects (59 positive and 40 negative for SARS-CoV-2 infection) examined for SARS-CoV-2. We find that miR-155 is significantly elevated in patients who tested positive relative to those who tested negative for SARS-CoV-2 infection. Additionally, 34% (n=20) of the patients positive for SARS-CoV-2 infection showed ≥ 2-fold upregulation of miR-155 relative to those who tested negative for SARS-CoV-2 infection ( Figs. 2A and 2B) . Further, in the gender-wise grouping analyses, the level of miR-155 expression is higher in male (n=21, positive versus n=18 negative for SARS-CoV-2 infection) relative to female (n=38, positive versus n=22, negative for SARS-CoV-2 infection) patients (Fig. 2C) . These results indicate that miR-155 is a potential target for COVID-19 therapy.

We evaluated the efficacy of in vivo delivery of anti-miR-155 to the lungs of SARS-CoV-2- Total RNA was isolated from the lungs of tg-mice and the expression of miR-155 was measured using miR-155-specifc Taqman assay. As depicted in Fig. 3A , a significant suppression of miR-155 (~30%) is observed in the lung tissues of SARS-CoV-2-infected anti-miR-155-treated tg-mice (n=6) compared to anti-miR-control tg-mice (n=3). These results demonstrate the effectiveness of anti-miR-155, administered via retro-orbital injection, in suppressing miR-155 in the lung tissues of SARS-CoV-2-infected tg-mice. The dose and administration regime will have to be further optimized.

We examined the effect of anti-miR-155 treatment on BW and survival of tg-mice hACE2 infected with SARS-CoV-2. The anti-miR-155-treated infected tg-mice (n=6) had relatively higher survival compared to the anti-miR-control-treated mice (n=3) (Fig. 3B) . All control mice succumbed to infection and were euthanized on 5 dpi, while the anti-miR-treated tg-mice survived a day longer and succumbed to infection and were euthanized on 6 dpi. Further, we observed that the anti-miR-155-treated tg-mice showed a slight increase in or stable BW (with a peak during days 2-4), compared to control tg-mice (Fig. 3C) . However, subsequently the animals from both anti-miR-155-treated and control group developed clinical signs of disease (weight loss, mild ruffled and hunched back, lethargic, not alert and difficulty breathing). From 4 dpi onwards, SARS-CoV-2-infected anti-miR-155-treated tg-mice as well as control mice displayed a rapid reduction in BW (Fig. 3C) . These results emphasize the role of anti-miR-155-based therapeutics for COVID-19 and suggests that perhaps a more frequent administration regime, i.e., treatment on alternate days post-infection, could improve the therapeutic efficacy.

We evaluated the responses of anti-miR-155 treatment on cytokine and chemokine profile in the lungs of SARS-CoV-2-infected tg-mice. Comprehensive analyses of cytokine profile (Luminex, 36-plex MILLIPLEX® MAP Mouse Cytokine/ Chemokine Magnetic Bead kit, EMD Millipore) in the bronchoalveolar lavage (BAL) fluid indicate attenuation of the "cytokine storm" in anti-miR-155-treated tg-mice (n=5) compared to control mice (n=1). We were unable to obtain BAL fluid from one of the treated tg-mice and 2 control tg-mice. The data indicate significant downregulation of cytokines and chemokines including G-CSF, IL-1α, IL-9, IL-12 (p70), KC, LIX, MIP-2, and VEGF (Fig. 4) . Additionally, other cytokines, which are relevant to SARS-CoV-2 infection, such as eotaxin, IFN-, IP-10, MCP-1, M-CSF, MIG, MIP-1α, MIP-1β, and TNF-α are induced in anti-miR-155-treated tg-mice compared to control tg-mice (Fig. 5) . Importantly, a significant elevation of IFN-, IP-10, and TNF-α suggests the antiviral potency of anti-miR-155 in addition to its anti-inflammatory efficacy in the tg-mice model of COVID-19. These data collectively suggest the anti-inflammatory as well as the anti-viral potency of anti-miR-155 therapy for COVID-19. 

Ninety-nine human subjects (39 male and 60 female; median age, 32 years; range, 12 to 84 ), who were examined for SARS-CoV-2 infection at OPKO Health Company (GeneDx, Inc., MD, USA) were included in this study. Nasopharyngeal swab samples were collected in 3mL of standard viral transportation media (VTM). Tubes containing the swab and VTM were pulse-vortexed three times and 1.5mL aliquots were collected onto low protein binding tubes (ThermoFisher cat# 88379). Tubes were then centrifuged at 4⁰C for 10 minutes at 1500g. VTM was carefully removed from the tubes and RNA was extracted from pelleted cells. The 

For analyses of miRNA expression, the RNA was extracted from the VTM using the RNAqueous Micro Kit (ThermoFisher), following manufacturer specifications. During RNA isolation, 100fmol of cel-miR-39 RNA (Ambion) was added as spike-in-control. The expression of miR-155 and cel-miR-39 were analyzed by specific Taqman assays (ThermoFisher). Cel-miR-39 was used as an endogenous control to normalize expression. The relative fold changes of miR-155 were analyzed using the 2 -ΔΔCT method.

Eight to ten weeks old mice transgenic for human angiotensin I-converting enzyme 2 receptor via Retro-Orbital (RO) injections. A set of control infected tg-mice (n=3) were treated similarly with anti-miR (scrambled)-control. Following the infection of tg-mice with SARS-CoV-2, the lungs from the set of control tg-mice treated with anti-miR (scrambled)-control were isolated on 5 dpi, and the lungs from the anti-miR-155-treated tg-mice were isolated on 6 dpi. All isolated lungs from control and treated tg-mice were immediately snap-frozen over dry ice and stored at -80 ᴼ C.

The total RNA was isolated from frozen lung tissues using TriZol reagent (Invitrogen Inc., Carlsbad, CA) with a mirVana TM miRNA isolation kit (Ambion, AM1561) and quantitated using Nanodrop (Thermo Scientific). MiRNAs analysis was performed with specific Taqman probes and U6 was used as an endogenous control to normalize expression of miR-155. The relative fold changes of miR-155 were analyzed using the 2 -ΔΔCT method.

The level of cytokine and chemokines protein in BAL samples from anti-miR-155-treated tgmice hACE2 and anti-miR (scrambled)-control tg-mice hACE2 were analyzed by Luminex multiplex assays using 36-plex MILLIPLEX® MAP Mouse Cytokine / Chemokine Magnetic Bead kit, (EMD Millipore) according to the manufacturer's protocol.

Statistical analysis for viral load and miR-155 expression was performed using Excel. The 

China Medical Treatment Expert Group for C. Clinical Characteristics of Coronavirus Disease 2019 in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Virological assessment of hospitalized patients with COVID-2019

Targeting inflammation and cytokine storm in COVID-19

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Hlh Across Speciality Collaboration UK. COVID-19: consider cytokine storm syndromes and immunosuppression

Viral and host factors related to the clinical outcome of COVID-19

Interferon modulation of cellular microRNAs as an antiviral mechanism

MicroRNAs and the immune response to respiratory virus infections

MicroRNAs: the fine-tuners of Toll-like receptor signalling

MicroRNAs regulate immune system via multiple targets

Prediction of human microRNA targets

A pancreatic islet-specific microRNA regulates insulin secretion

MicroRNA gene expression deregulation in human breast cancer

miRNAs and apoptosis: RNAs to die for

miRNAs in cancer: approaches, aetiology, diagnostics and therapy

microRNAs and the regulation of glucose and lipid metabolism

MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets

MicroRNome analysis unravels the molecular basis of SARS infection in bronchoalveolar stem cells

Human coronavirus OC43 nucleocapsid protein binds microRNA 9 and potentiates NF-kappaB activation

miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice

Silencing of microRNAs in vivo with 'antagomirs'

The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities

MicroRNAs make big impression in disease after disease

Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM

miR-155: an ancient regulator of the immune system

Role of miR-155 in the regulation of lymphocyte immune function and disease

A Single miRNA-mRNA Interaction Affects the Immune Response in a Context-and Cell-Type-Specific Manner

The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types

MicroRNA-155 is induced during the macrophage inflammatory response

The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling

MicroRNA miR-155 affects antiviral effector and effector Memory CD8 T cell differentiation

Critical role of microRNA-155 in herpes simplex encephalitis

MicroRNA-155 controls Toll-like receptor 3-and hepatitis C virus-induced immune responses in the liver

MicroRNA-155 Controls T Helper Cell Activation During Viral Infection

MicroRNA expression profile of mouse lung infected with 2009 pandemic H1N1 influenza virus

Differential microRNA expression following infection with a mouseadapted, highly virulent avian H5N2 virus

Epigenetic and Transcriptomic Regulation of Lung Repair during Recovery from Influenza Infection

Increased expression of microRNA-155-5p by alveolar type II cells contributes to development of lethal ARDS in H1N1 influenza A virus-infected mice

The role of miR-155 in cigarette smoke-induced pulmonary inflammation and COPD

The trinity of COVID-19: immunity, inflammation and intervention

Regulation of the germinal center response by microRNA-155

miR-155 and its starform partner miR-155* cooperatively regulate type I interferon production by human plasmacytoid dendritic cells

Roles of microRNAs in the life cycles of mammalian viruses

An update on the role of miRNA-155 in pathogenic microbial infections

MicroRNAs as regulatory elements in immune system logic

MicroRNA 155 and viral-induced neuroinflammation

Environmental pollutants modulate RNA and DNA virus-activated miRNA-155 expression and innate immune system responses: Insights into new immunomodulative mechanisms

Bulk and single-cell gene expression profiling of SARS-CoV-2 infected human cell lines identifies molecular targets for therapeutic intervention

Prediction and Analysis of SARS-CoV-2-Targeting MicroRNA in Human Lung Epithelium

COVID-19 preclinical models: human angiotensinconverting enzyme 2 transgenic mice

Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease

SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function

Pathogenesis of SARS-CoV-2 in Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2

An inflammatory cytokine signature predicts COVID-19 severity and survival

Drug repurposing and cytokine management in response to COVID-19: A review

The COVID-19 Cytokine Storm

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

The authors thank Samarjit Das (Johns Hopkins University) for helpful discussions, Maciel Porto (Bioqual Inc.) for monitoring the animal study and performing Luminex assays, and Melissa Hamilton (Bioqual Inc.) for processing and analyses of data.

This study was supported by NHLBI/USUHS-CHIRP funds 1I80VP000012 and USUHS Intramural